SCHEMBL32690494

SCHEMBL32690494

N=C(N)NCCC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NRP1 O14786 1/20 0.46
▸ NMUR2 Q9GZQ4 2/20 0.46
▸ NMUR1 Q9HB89 2/20 0.46
▸ CXCR4 P61073 2/20 0.45
▸ OPRM1 P35372 6/20 0.44
▸ OPRK1 P41145 6/20 0.44
▸ MAPK8 P45983 1/20 0.44
▸ MAPK9 P45984 1/20 0.44
▸ MAPK10 P53779 1/20 0.44
▸ KDM1A O60341 2/20 0.43
▸ MAOB P27338 1/20 0.43
▸ KDM5A P29375 1/20 0.43
▸ KDM1B Q8NB78 1/20 0.43
▸ F2 P00734 1/20 0.43
▸ NTSR2 O95665 2/20 0.43
▸ NTSR1 P30989 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30811140 0.96 NMUR2 (0.49) NRP1NMUR2NMUR1CXCR4OPRM1
SCHEMBL29906667 0.91 NRP1 (0.52) NRP1CXCR4OPRM1OPRK1F2
SCHEMBL29872595 0.91 NRP1 (0.54) NRP1OPRM1OPRK1F2NTSR2
SCHEMBL24485493 0.90 F2 (0.49) NRP1NMUR2NMUR1CXCR4OPRM1
SCHEMBL32690579 0.90 OPRM1 (0.48) NRP1CXCR4OPRM1OPRK1F2
SCHEMBL30855542 0.89 NRP1 (0.49) NRP1NMUR2NMUR1OPRM1OPRK1
SCHEMBL31399622 0.89 NRP1 (0.49) NRP1NMUR2NMUR1OPRM1OPRK1
SCHEMBL31267968 0.89 F2 (0.49) NRP1CXCR4OPRM1OPRK1KDM1A
SCHEMBL7759489 0.88 MAPK8 (0.45) NRP1NMUR2NMUR1CXCR4OPRM1
SCHEMBL7759499 0.88 MAPK8 (0.45) NRP1NMUR2NMUR1CXCR4OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083865-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2026-03-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083865-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF KLK3, FOLH1, PSMA1 NRP1 2149/4885NMUR2 1227/4885NMUR1 1007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback